The share capital of Genmab A/S has been increased. The admittance to trading
and official listing will take effect as per 15 December 2023 in the ISIN
below.
ISIN: DK0010272202
------------------------------------------------------------
Name: Genmab
------------------------------------------------------------
Volume before change: 66.067.481 shares (DKK 66.067.481)
------------------------------------------------------------
Change: 7,054 shares (DKK 7,054)
------------------------------------------------------------
Volume after change: 66,074,535 shares (DKK 66,074,535)
------------------------------------------------------------
Subscription prices: · 1,106 shares - DKK 1,025.00
· 3,453 shares - DKK 1,145.00
· 300 shares - DKK 1,147.50
· 85 shares - DKK 1,161.00
· 70 shares - DKK 1,210.00
· 20 shares - DKK 1,334.50
· 50 shares - DKK1,362.50
· 144 shares - DKK 1,402.00
· 40 shares - DKK 1,408.00
· 294 shares - DKK 1,424.00
· 1,492 shares - DKK 1,615.00
------------------------------------------------------------
Face value: DKK 1
------------------------------------------------------------
Short name: GMAB
------------------------------------------------------------
Orderbook ID: 11143
------------------------------------------------------------
For further inform-ion, please contact: Surveillance, tel. +45 33 93 33 661-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 275,60 | 278,40 | 15.05. | |
| 275,60 | 277,50 | 15.05. |
Nasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise
© 2023 GlobeNewswire
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Genmab A/S: Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress | Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development program Three oral presentations highlight novel data... ► Artikel lesen | |
| Mo | GENMAB A/S - 6-K, Report of foreign issuer | ||
| Mo | Genmab A/S: Transactions in Connection with Share Buy-back Program | ||
| Mo | Nasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise | The share capital of Genmab A/S has been increased. The admittance to trading
and official listing will take effect as per 14 May 2024 in the ISIN below.
ISIN: DK0010272202
------------------------------------------------------------
Name:... ► Artikel lesen | |
| 07.05. | Genmab A/S: Capital Increase in Genmab as a Result of Employee Warrant Exercise |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
